CircDENND2D’s ability to suppress PD-L1 and enhance CD8+ T cell function has been validated in vitro and in vivo, but its delivery to lung tumors remains a challenge—current in vivo studies use intratumoral injection, which is not feasible for advanced lung cancer. This evidence concerns the gene CD8A and lung carcinoma.